Buscar
Passage Bio Inc
PASGAñadir a la lista de seguimiento
5.000USD
+0.050+1.01%
Cierre 09-23 16:00（ET）
16.05MCap. mercado
PérdidaP/E TTM
Acerca de Passage Bio Inc Compañía
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Perfil de Passage Bio Inc
Símbolo de cotizaciónPASG
Nombre de la empresaPassage Bio Inc
Fecha de salida a bolsaFeb 28, 2020
Director ejecutivoChou (William)
Número de empleados60
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 28
DirecciónOne Commerce Square
CiudadPHILADELPHIA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19103
Teléfono12678660312
Sitio Webhttps://www.passagebio.com/
Símbolo de cotizaciónPASG
Fecha de salida a bolsaFeb 28, 2020
Director ejecutivoChou (William)
Ejecutivos de Passage Bio Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. William Chou, M.D.
Dr. William Chou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.72K
--
Dr. William Chou, M.D.
Dr. William Chou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.72K
--
Ms. Kathleen Borthwick
Ms. Kathleen Borthwick
Chief Financial Officer
Chief Financial Officer
5.41K
+0.18%
Ms. Kathleen Borthwick
Ms. Kathleen Borthwick
Chief Financial Officer
Chief Financial Officer
5.41K
+0.18%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
945.00
--
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
945.00
--
Mr. Sandip S. Kapadia, CPA
Mr. Sandip S. Kapadia, CPA
Independent Director
Independent Director
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Independent Chairperson of the Board
Independent Chairperson of the Board
--
--
Dr. Derrell D. Porter, M.D.
Dr. Derrell D. Porter, M.D.
Independent Director
Independent Director
--
--
Dr. Dolan Sondhi, Ph.D.
Dr. Dolan Sondhi, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. William Chou, M.D.
Dr. William Chou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.72K
--
Dr. William Chou, M.D.
Dr. William Chou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.72K
--
Ms. Kathleen Borthwick
Ms. Kathleen Borthwick
Chief Financial Officer
Chief Financial Officer
5.41K
+0.18%
Ms. Kathleen Borthwick
Ms. Kathleen Borthwick
Chief Financial Officer
Chief Financial Officer
5.41K
+0.18%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
945.00
--
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
945.00
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Passage Bio Inc?
Los cinco principales accionistas de Passage Bio Inc son: Dr. William Chou, M.D.
¿Cuántas instituciones poseen acciones de Passage Bio Inc (PASG)?
A fecha de 2026Q1, 94 instituciones poseen acciones de Passage Bio Inc, con un valor de mercado combinado de aproximadamente 1.82M, lo que representa el 56.60% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -203071.00.